Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | HMGCR | P04035 | 11/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.83 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenivastatin SCHEMBL28594403 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL28594405 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL14137685 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL3694911 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL14420544 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL13934502 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL25366987 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL8239454 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL28618339 | 0.99 | SLCO1B1 (0.98) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL2987588 | 0.99 | SLCO1B1 (0.98) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116744934-A | Inhaled statins for the treatment of viral respiratory diseases | 加利福尼亚大学董事会 | 2023-09-12 | — | — | CN | claimed |
| US-20230172849-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | UNIV CALIFORNIA (US) | 2023-06-08 | — | — | US | claimed |
| EP-4146340-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-15 | — | — | EP | claimed |
| US-20230014352-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-01-19 | — | — | US | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2021226479-A1 | INHALED STATINS FOR TREATMENT OF VIRAL RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-11 | — | — | WO | claimed |
| EP-2923698-B1 | STATIN COMPOUND FOR USE IN TREATING OBESITY, HYPERTENSION AND HYPERLIPAEMIA BY INTRAOSSEOUS ADMINISTRATION | UNIV PEKING THIRD HOSPITAL (CN) | 2021-04-28 | — | — | EP | claimed |
| WO-2020205663-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-08 | — | — | WO | claimed |
| EP-3290022-B1 | USE OF STATINS IN THE TREATMENT OF ISCHEMIC DISEASES | UNIV PEKING THIRD HOSPITAL (CN) | 2020-04-01 | — | — | EP | claimed |
| US-10179121-B2 | Use of statins in the treatment of ischemic diseases | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2019-01-15 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1951224-A2 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | Aegerion Pharmaceuticals (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1945205-A2 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | Aegerion Pharmaceuticals (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007120144-A1 | BIOACTIVE-RICH CONCENTRATES AND NUTRITIVE AND THERAPEUTIC PRODUCTS CONTAINING SAME | NATURI LLC (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070243233-A1 | Bioactive-rich concentrates and nutritive and therapeutic products containing same | NATURI LLC (US) | 2007-10-18 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007047880-A2 | COMPOSITIONS FOR LOWERING SERUM CHOLESTEROL AND/OR TRIGLYCERIDES | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | claimed |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | AEGERION PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | claimed |
| WO-2007047725-A2 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | HMGCR, MTTP, CETP | SLCO1B1 563/4885HMGCR 1/4885HDAC1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.